[
  {
    "ts": "2025-10-20T18:03:00+00:00",
    "headline": "Elon Musk takes shot at rival facing major problem",
    "summary": "Amazon has grown since it launched as an online bookstore in 1995 to become the dominant player in web hosting 30 years later. Amazon Web Services (AWS) was launched in 2006, and over the last decade, it has become the largest cloud computing provider in the world. AWS generated $107.6 billion in ...",
    "url": "https://www.thestreet.com/technology/elon-musk-takes-shot-at-a-rival-that-just-made-a-huge-mistake",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "34fbcedc-26df-37fa-a256-9ed585c931f3",
      "content": {
        "id": "34fbcedc-26df-37fa-a256-9ed585c931f3",
        "contentType": "STORY",
        "title": "Elon Musk takes shot at rival facing major problem",
        "description": "",
        "summary": "Amazon has grown since it launched as an online bookstore in 1995 to become the dominant player in web hosting 30 years later. Amazon Web Services (AWS) was launched in 2006, and over the last decade, it has become the largest cloud computing provider in the world. AWS generated $107.6 billion in ...",
        "pubDate": "2025-10-20T18:03:00Z",
        "displayTime": "2025-10-20T18:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/2fdf4fe3b6b449955fe2a3d7e11de499",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CRZWEAbZSAl59w438VJk3A--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/2fdf4fe3b6b449955fe2a3d7e11de499.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/txwkUWA_UgxLAJC.feonyw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/2fdf4fe3b6b449955fe2a3d7e11de499.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/technology/elon-musk-takes-shot-at-a-rival-that-just-made-a-huge-mistake",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/elon-musk-takes-shot-rival-180300723.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "ADBE"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "COF"
            },
            {
              "symbol": "DIS"
            },
            {
              "symbol": "BMW.DE"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T14:15:00+00:00",
    "headline": "Pfizer's Q3 Non-Oncology Performance: Here's What to Expect",
    "summary": "Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.",
    "url": "https://finance.yahoo.com/news/pfizers-q3-non-oncology-performance-141500807.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8432b2cb-0dc7-3920-97aa-f4c352deb281",
      "content": {
        "id": "8432b2cb-0dc7-3920-97aa-f4c352deb281",
        "contentType": "STORY",
        "title": "Pfizer's Q3 Non-Oncology Performance: Here's What to Expect",
        "description": "",
        "summary": "Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.",
        "pubDate": "2025-10-20T14:15:00Z",
        "displayTime": "2025-10-20T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YqcOBKMNrThKvJSga1KIbw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Vj9Bix098SQE5mY9G0P2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-q3-non-oncology-performance-141500807.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-q3-non-oncology-performance-141500807.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T14:10:00+00:00",
    "headline": "Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings",
    "summary": "ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.",
    "url": "https://finance.yahoo.com/news/heres-expect-abbvies-oncology-segment-141000379.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "06f819ae-9015-3878-8716-7181eecf3a8a",
      "content": {
        "id": "06f819ae-9015-3878-8716-7181eecf3a8a",
        "contentType": "STORY",
        "title": "Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings",
        "description": "",
        "summary": "ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.",
        "pubDate": "2025-10-20T14:10:00Z",
        "displayTime": "2025-10-20T14:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NXvq4ox9.Dlnga3rarSarw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ut1qVl6so81FolVpx3AkvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-abbvies-oncology-segment-141000379.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-abbvies-oncology-segment-141000379.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T14:10:00+00:00",
    "headline": "How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?",
    "summary": "CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.",
    "url": "https://finance.yahoo.com/news/defencath-aid-crmds-top-line-141000778.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "b710721e-3561-3e0d-963b-7450f048b15f",
      "content": {
        "id": "b710721e-3561-3e0d-963b-7450f048b15f",
        "contentType": "STORY",
        "title": "How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?",
        "description": "",
        "summary": "CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.",
        "pubDate": "2025-10-20T14:10:00Z",
        "displayTime": "2025-10-20T14:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OAiu5He0SiZzKJ7weu9Org--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xHxlTKesMnS_SkMo1hl1jw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/defencath-aid-crmds-top-line-141000778.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/defencath-aid-crmds-top-line-141000778.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CRMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T08:38:32+00:00",
    "headline": "Pfizer, Astellas Pharma Say Drug Combination Reduces Risk of Prostate Cancer Death",
    "summary": "Pfizer (PFE) and Astellas Pharma US said Sunday that the drug combination Xtandi and leuprolide for",
    "url": "https://finance.yahoo.com/news/pfizer-astellas-pharma-drug-combination-083832255.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "b211a84e-a6c9-3fc4-9d5f-9ebf9bf1ace5",
      "content": {
        "id": "b211a84e-a6c9-3fc4-9d5f-9ebf9bf1ace5",
        "contentType": "STORY",
        "title": "Pfizer, Astellas Pharma Say Drug Combination Reduces Risk of Prostate Cancer Death",
        "description": "",
        "summary": "Pfizer (PFE) and Astellas Pharma US said Sunday that the drug combination Xtandi and leuprolide for",
        "pubDate": "2025-10-20T08:38:32Z",
        "displayTime": "2025-10-20T08:38:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-astellas-pharma-drug-combination-083832255.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-astellas-pharma-drug-combination-083832255.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]